| 2.13 -0.09 (-4.05%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.62  |
1-year : | 3.06 |
| Resists | First : | 2.25 |
Second : | 2.62 |
| Pivot price | 1.96 |
|||
| Supports | First : | 1.74 |
Second : | 1.44 |
| MAs | MA(5) : | 2.14 |
MA(20) : | 1.94 |
| MA(100) : | 1.74 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 92.1 |
D(3) : | 89.2 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 5.09 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SNTI ] has closed below upper band by 32.5%. Bollinger Bands are 79% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.25 - 2.26 | 2.26 - 2.27 |
| Low: | 2.03 - 2.05 | 2.05 - 2.05 |
| Close: | 2.11 - 2.13 | 2.13 - 2.15 |
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
Thu, 04 Dec 2025
Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting - Quiver Quantitative
Fri, 21 Nov 2025
Leerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform Recommendation - Nasdaq
Thu, 13 Nov 2025
Senti Biosciences Reports Third Quarter 2025 Financial Results and Pipeline Updates - Quiver Quantitative
Thu, 13 Nov 2025
Senti Biosciences Reports Q3 2025 Financial Results - TipRanks
Thu, 16 Oct 2025
Senti Biosciences CEO Timothy Lu to Present at Chardan's 9th Annual Genetic Medicines Conference - Quiver Quantitative
Tue, 14 Oct 2025
HC Wainwright & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 56.7 (%) |
| Held by Institutions | 22.2 (%) |
| Shares Short | 178 (K) |
| Shares Short P.Month | 231 (K) |
| EPS | -2.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -67.8 % |
| Return on Equity (ttm) | -394.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.44 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.75 |
| PEG Ratio | 0 |
| Price to Book value | 6.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|